These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 28806948)

  • 41. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms.
    Stock RG; Stone NN; Dahlal M; Lo YC
    Brachytherapy; 2002; 1(2):83-9. PubMed ID: 15062175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning.
    Matzkin H; Kaver I; Stenger A; Agai R; Esna N; Chen J
    Urology; 2003 Sep; 62(3):497-502. PubMed ID: 12946754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
    Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
    Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [PSA bounce phenomenon after transperineal interstitial permanent prostate brachytherapy for localized prostate cancer].
    Morita M; Lederer JL; Fukagai T; Shimada M; Yoshida H
    Nihon Hinyokika Gakkai Zasshi; 2004 Mar; 95(3):609-15. PubMed ID: 15103924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Urethral dose and increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer.
    Murakami N; Itami J; Okuma K; Marino H; Nakagawa K; Ban T; Nakazato M; Kanai K; Naoi K; Fuse M
    Strahlenther Onkol; 2008 Oct; 184(10):515-9. PubMed ID: 19016040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity.
    Merrick GS; Butler WM; Wallner K; Galbreath RW; Anderson RL; Kurko BS; Lief JH
    Urology; 2002 Jul; 60(1):104-8. PubMed ID: 12100933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical features of prostate-specific antigen bounce after 125I brachytherapy for prostate cancer.
    Kubo K; Wadasaki K; Kimura T; Murakami Y; Kajiwara M; Teishima J; Matsubara A; Nagata Y
    J Radiat Res; 2018 Sep; 59(5):649-655. PubMed ID: 30085076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical significance of peripheral zone thickness in men with lower urinary tract symptoms/benign prostatic hyperplasia.
    Kwon JK; Han JH; Choi HC; Kang DH; Lee JY; Kim JH; Oh CK; Choi YD; Cho KS
    BJU Int; 2016 Feb; 117(2):316-22. PubMed ID: 25807886
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prediction of urinary symptoms after 125iodine prostate brachytherapy.
    Kelly K; Swindell R; Routledge J; Burns M; Logue JP; Wylie JP
    Clin Oncol (R Coll Radiol); 2006 May; 18(4):326-32. PubMed ID: 16703751
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Useful parameters to predict the presence of detrusor overactivity in male patients with lower urinary tract symptoms.
    Matsukawa Y; Majima T; Ishida S; Funahashi Y; Kato M; Gotoh M
    Neurourol Urodyn; 2020 Jun; 39(5):1394-1400. PubMed ID: 32259358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
    Meyer A; Wassermann J; Warszawski-Baumann A; Baumann R; Machtens S; Karstens JH; Christiansen H; Merseburger A; Kuczyk MA; von Klot C
    BJU Int; 2013 May; 111(6):897-904. PubMed ID: 23305079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Temporal resolution of urinary morbidity following prostate brachytherapy.
    Merrick GS; Butler WM; Lief JH; Dorsey AT
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):121-8. PubMed ID: 10758313
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prostate-specific antigen bounce after curative brachytherapy for early-stage prostate cancer: A study of 274 African-Caribbean patients.
    Leduc N; Atallah V; Creoff M; Rabia N; Taouil T; Escarmant P; Vinh-Hung V
    Brachytherapy; 2015; 14(6):826-33. PubMed ID: 26489920
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic Tool for Assessing Overactive Bladder Symptoms: Could the International Prostate Symptom Storage Subscore Replace the Overactive Bladder Symptom Score?
    Shim JS; Kim JH; Choi H; Park JY; Bae JH
    Int Neurourol J; 2016 Sep; 20(3):209-213. PubMed ID: 27706011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Overactive bladder symptom score to evaluate efficacy of solifenacin for the treatment of overactive bladder symptoms.
    Liu M; Wang J; Yang Y; An R; Wen J; Guan Z; Zheng S; Wang D; Song B; Liao L; Guo H; Xiao J; Sun Y; Shen Z; Kong C; He D; Huang Y; Wang X; Zhang X; Li H; Huang J; Zhao X; Zeng P; Song X; Ye Z
    Chin Med J (Engl); 2014; 127(2):261-5. PubMed ID: 24438613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].
    Wada N; Hashidume K; Tamaki G; Kita M; Iwata T; Matsumoto S; Kakizaki H
    Hinyokika Kiyo; 2012 Sep; 58(9):475-80. PubMed ID: 23070385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factors affecting urinary frequency after low-dose-rate brachytherapy for prostate cancer.
    Uematsu T; Torimoto K; Tanaka N; Asakawa I; Hori S; Yamaki K; Nakai Y; Miyake M; Anai S; Hasegawa M; Fujimoto K
    Low Urin Tract Symptoms; 2022 Jan; 14(1):4-9. PubMed ID: 34288506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Iodine-125 seed implantation and deferred transurethral resection of the prostate for patients with lower urinary tract symptoms and localized prostate cancer.
    Liu R; Luo F; Zhang Z; Xu Y
    Clin Genitourin Cancer; 2013 Sep; 11(3):251-5. PubMed ID: 23375828
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.